Infinity Pharmaceuti (INFI) |
|
1.18 0 (0%)
|
10-23 23:41 |
|
Open: |
1.18 |
Pre. Close: |
1.18 |
|
High:
|
1.2 |
Low:
|
1.17 |
|
Volume:
|
149,351 |
Market Cap:
|
69M |
|
|
|
|
Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 25 full-time employees. The firm is engaged in the discovery, development and delivery of medicines to treat diseases. The firm develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The firm is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The firm also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.203 - 1.209 |
1.209 - 1.214 |
|
Low:
|
1.154 - 1.162 |
1.162 - 1.168 |
|
Close:
|
1.169 - 1.181 |
1.181 - 1.191 |
|
Technical analysis |
as of: 2020-10-23 4:45:21 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 1.51 One year: 1.76 |
| Support: |
Support1: 1.11 Support2:  |
| Resistance: |
Resistance1: 1.29 Resistance2: 1.51 |
| Pivot: |
1.18 |
| Moving Average: |
MA(5): 1.19 MA(20): 1.17
MA(100): 1.03 MA(250): 1.06 |
| MACD: |
MACD(12,26): 0.02 Signal(9): 0.03 |
| Stochastic oscillator: |
%K(14,3): 41.67 %D(3): 46.88 |
| RSI: |
RSI(14): 53.17 |
| 52-week: |
High: 1.68 Low: 0.60 Change(%): 9.3 |
| Average Vol(K): |
3-Month: 57376 10-Days: 28196 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.INFI has closed above bottom band by 48.1%. Bollinger Bands are 26.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 21 Oct 2020
Bulls Are Starting To Focus In On Infinity Pharmaceuticals, Inc. (INFI) - Invest Million
Thu, 15 Oct 2020
Reflecting on Infinity Pharmaceuticals’ (NASDAQ:INFI) Share Price Returns Over The Last Five Years - Simply Wall St
Sun, 11 Oct 2020
Would Shareholders Who Purchased Infinity Pharmaceuticals' (NASDAQ:INFI) Stock Five Years Be Happy With The Share price Today? - Yahoo Finance
Mon, 05 Oct 2020
Hot Stock Spotlight: Infinity Pharmaceuticals, (INFI) | Armenian American Reporter - Armenian Reporter
Wed, 30 Sep 2020
Why Infinity Pharmaceuticals Inc. (INFI) Is in Such Horrid Condition - The News Heater
Wed, 30 Sep 2020
Oppenheimer slashes price target on Infinity Pharmaceuticals Inc. [INFI] – find out why. - The DBT News
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Underperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Underperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
59 |
| Shares Float (M) |
36 |
|
% Held by Insiders
|
3.51 |
|
% Held by Institutions
|
50.64 |
|
Shares Short (K)
|
78 |
|
Shares Short P. Month (K)
|
149 |
Stock Financials |
|
EPS
|
-0.754 |
|
EPS Est This Year
|
-0.920 |
|
EPS Est Next Year
|
-1.500 |
|
Book Value (p.s.)
|
-0.200 |
|
Profit Margin
|
|
|
Operating Margin
|
-2889.71 |
|
Return on Assets (ttm)
|
-44.4 |
|
Return on Equity (ttm)
|
-474.7 |
|
Qtrly Rev. Growth
|
40.1 |
|
Gross Profit (p.s.)
|
-0.533 |
|
Sales Per Share
|
0.024 |
|
EBITDA (p.s.)
|
-0.698 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-38 |
|
Levered Free Cash Flow (M)
|
-27 |
Stock Valuations |
|
PE Ratio
|
-1.56 |
|
PEG Ratio
|
|
|
Price to Book value
|
-5.90 |
|
Price to Sales
|
48.24 |
|
Price to Cash Flow
|
-1.83 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
